 Zynerba Pharmaceuticals Inc has provided program updates for Fragile X syndrome FXS, autism spectrum disorder ASD, 22q11.2 deletion syndrome 22q, and developmental and epileptic encephalopathies DEE. In addition to the continued clinical development of its Zygel CBD gel in FXS, the company said it plans to focus on the development of Zygel in ASD and 22q. 